Tags

Type your tag names separated by a space and hit enter

Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Prescrire Int. 1999 Aug; 8(42):116-20.PI

Abstract

(1) In primary prevention trials, pravastatin and lovastatin prevented myocardial infarction and had a positive risk-benefit ratio in men with LDL-cholesterol values exceeding 4.5 mmol/l (1.7 g/l). Cholestyramine and gemfibrozil also prevented myocardial infarction in men with more severe hypercholesterolaemia; while clofibrate had a negative risk-benefit ratio in patients with moderate hypercholesterolaemia. These treatments have not been assessed for primary prevention in women or in patients aged over 70. (2) In trials involving patients with coronary heart disease, pravastatin and simvastatin both reduced the risk of myocardial infarction and/or mortality in patients of both sexes with LDL-cholesterol values above 3.2 mmol/l (1.2 g/l). Gemfibrozil also reduced the risk of myocardial infarction but not mortality, while clofibrate and bezafibrate had no preventive effect.

MeSH

Anticholesteremic AgentsBezafibrateCholestyramine ResinClinical Trials as TopicClofibrateFemaleGemfibrozilHumansHypercholesterolemiaLovastatinMaleMyocardial InfarctionPravastatinTreatment Outcome

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

11503831

Citation

"Cholesterol-lowering Drugs. some Drugs With Demonstrated Efficacy but Different Benefits in Primary and Secondary Prevention." Prescrire International, vol. 8, no. 42, 1999, pp. 116-20.
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. Prescrire Int. 1999;8(42):116-20.
(1999). Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. Prescrire International, 8(42), 116-20.
Cholesterol-lowering Drugs. some Drugs With Demonstrated Efficacy but Different Benefits in Primary and Secondary Prevention. Prescrire Int. 1999;8(42):116-20. PubMed PMID: 11503831.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. PY - 2001/8/16/pubmed PY - 2001/8/17/medline PY - 2001/8/16/entrez SP - 116 EP - 20 JF - Prescrire international JO - Prescrire Int VL - 8 IS - 42 N2 - (1) In primary prevention trials, pravastatin and lovastatin prevented myocardial infarction and had a positive risk-benefit ratio in men with LDL-cholesterol values exceeding 4.5 mmol/l (1.7 g/l). Cholestyramine and gemfibrozil also prevented myocardial infarction in men with more severe hypercholesterolaemia; while clofibrate had a negative risk-benefit ratio in patients with moderate hypercholesterolaemia. These treatments have not been assessed for primary prevention in women or in patients aged over 70. (2) In trials involving patients with coronary heart disease, pravastatin and simvastatin both reduced the risk of myocardial infarction and/or mortality in patients of both sexes with LDL-cholesterol values above 3.2 mmol/l (1.2 g/l). Gemfibrozil also reduced the risk of myocardial infarction but not mortality, while clofibrate and bezafibrate had no preventive effect. SN - 1167-7422 UR - https://www.unboundmedicine.com/medline/citation/11503831/Cholesterol_lowering_drugs__Some_drugs_with_demonstrated_efficacy_but_different_benefits_in_primary_and_secondary_prevention_ L2 - https://medlineplus.gov/heartattack.html DB - PRIME DP - Unbound Medicine ER -